Latest news with #PI3K
Yahoo
29-07-2025
- Business
- Yahoo
Relay Therapeutics has positive read from Celcuity data, says Barclays
After Celcuity (CELC) announced topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial evaluating gedatolisib plus fulvestrant with and without palbociclib versus fulvestrant Barclays analyst Peter Lawson said the data validate targeting the PI3K pathway in breast cancer, which has a positive read-through for Relay Therapeutics (RLAY). While gedatolisib could represent new competition, the firm continues to see important advantages in Relay's mutant selective approach and keeps an Overweight rating and $17 price target on Relay shares. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on RLAY: Disclaimer & DisclosureReport an Issue Claire Mazumdar Joins Relay Therapeutics as Director Relay Therapeutics Holds 2025 Annual Stockholder Meeting Relay Therapeutics Announces Lease Termination Agreement Relay Therapeutics announces updated data for RLY-2608 with Fulvestrant Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
07-03-2025
- Business
- Associated Press
Torqur AG Presents Interim Phase 2 Clinical Trial Results at American Academy of Dermatology (AAD) 2025 Annual Meeting
Torqur AG, an innovative clinical-stage biotechnology company dedicated to advancing treatments for oncology and dermatology, is delighted to announce the presentation of interim results from its ongoing Phase 2 clinical trial in Actinic keratosis at the American Academy of Dermatology (AAD) Annual Meeting, taking place in Orlando, Florida, from March 7–11, 2025. Actinic keratosis, the most common pre-cancerous dermatological condition, affects 58 million Americans each year. 1 Primarily driven by an overactive PI3K pathway, early research suggests targeted therapy could hold promise for many patients. The study evaluates the safety and efficacy of topical gel bimiralisib, a selective pan-PI3K/mTOR inhibitor, in patients with Actinic keratosis. The interim results highlight strong potential, paving the way for further clinical advancement. Key interim findings include: Efficacy: Bimiralisib topical gel (2%) demonstrated strong efficacy with 60% of patients who completed the initial treatment and follow up visit showing either complete or partial clearance of their lesions. Notably, 70% in the 4-week treatment group (Arm B, 17 patients) and 50% in the 2-week treatment group (Arm A, 18 patients) showed significant improvement, reinforcing its potential as an effective targeted therapy for Actinic keratosis. Safety: The safety profile indicates that bimiralisib topical gel (2%) was well tolerated, with treatment-related adverse events primarily being mild (Grade 1) and resolving quickly after treatment completion. 'These interim results mark a significant step forward in our commitment to bringing innovative therapeutic options to patients with Actinic keratosis,' said Dr. Vladimir Cmiljanovic, CEO at Torqur AG. 'We are highly encouraged by the positive trends observed and remain focused on advancing the study toward the next phase of development.' Prof. Dr. David Fisher, Chair of the Dermatology Department at Massachusetts General Hospital (MGH) and Harvard Medical School, offered: 'Most instances of cutaneous squamous cell carcinomas begin as Actinic keratosis. With more than 58 million Americans living with these lesions, new targeted, non-invasive treatments for early-stage growths could help to alleviate the burden of this disease for thousands of patients.' 'The interim results from this Phase 2 trial are highly encouraging, showing strong potential for bimiralisib topical gel (2%) as an effective and well-tolerated treatment for Actinic keratosis,' said Prof. Dr. Alexander Navarini, lead Principal Investigator and Chairman of the Department of Dermatology and Allergy at the University Hospital Basel in Switzerland. 'These encouraging interim findings further validate the need for effective, targeted therapies addressing the PI3K pathway in Actinic keratosis. We look forward to building on this momentum and further assessing bimiralisib's clinical potential as the study progresses.' Prof. Dr. Olivier Gaide, Principal Investigator and Head of the Center of Excellence for Skin Cancer and Melanoma at the Lausanne University Hospital, Switzerland, added: 'The interim results from this Phase 2 trial indicate promising efficacy and tolerability of bimiralisib topical gel (2%), reinforcing its potential as a valuable targeted therapy for Actinic keratosis.' The Phase 2 trial is enrolling patients across two renowned dermatology centers in Switzerland, Prof. Alexander Navarini in Basel and Prof. Olivier Gaide in Lausanne, with full results expected in June 2025. The complete interim analysis will be accessible to conference attendees through the AAD online viewing portal and on-site viewing stations starting at the beginning of the meeting. However, public access via the Journal of the American Academy of Dermatology supplement will occur later in the year. For more information on the trial, please visit ID NCT06319794. About Torqur AG Torqur AG, a Swiss biotech pioneer, focuses on developing novel anti-cancer therapies targeting the metabolic PI3K/mTOR pathway. Leveraging the assets and intellectual property acquired from Piqur Therapeutics AG, Torqur AG is at the forefront of cancer research and therapy development. Founded by Dr. Vladimir Cmiljanovic and Dr. Natasa Cmiljanovic, Torqur AG operates under the auspices of Swiss Rockets AG, driving innovation in oncology and dermatology. DISCLAIMER Swiss Rockets AG and Torqur AG have prepared this press release to the best of its knowledge, based on the currently available preliminary data. The general background information about Torqur AG's activities is current as of the date of this press release. This information is provided in summary form and does not claim to be exhaustive. The final results and outcomes of the study may materially differ from those projected in this slide deck. Torqur AG does not make any warranties, representations, or guarantees regarding the final results and outcomes of the study. The information contained in this press release does not constitute a solicitation or offer to buy, sell, or otherwise trade or engage in any similar transaction involving Swiss Rockets AG's or Torqur AG's shares. The information presented herein includes certain forward-looking statements and estimates. Such information is subject to significant scientific, economic, business, and financial uncertainties that cannot be predicted in advance. Therefore, actual results may materially differ from those projected. Neither Swiss Rockets AG nor its group companies make any warranties, representations, or guarantees regarding the data and information made available through this communication, including but not limited to their accuracy, timeliness, completeness, marketability, commercial usability, or suitability for any particular purpose and in particular with regard to forward-looking statements and does not make any warranties or gives any guarantees on the future course of development and success of any of its products, strategies or business activities. This disclaimer is governed by Swiss law. Any disputes arising from or in connection with this press release shall be subject to the exclusive jurisdiction of the competent courts of the Canton of Basel-Stadt, Switzerland. CONTACT: For media inquiries or further information, please contact:U.S. Media Contact Rachel Ford Hutman Ford Hutman Media [email protected] Media Contact Dr. Sabina R. Korfmann-Bodenmann INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY SOURCE: Torqur AG Copyright Business Wire 2025. PUB: 03/07/2025 10:29 AM/DISC: 03/07/2025 10:29 AM
